Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4233914 | 0.88 | SMN1; SMN2 (0.41) | RAB9ASMN1; SMN2NPC1LMNATSHR | |
| SCHEMBL4230804 | 0.81 | MAPT (0.51) | RAB9ASMN1; SMN2NPC1LMNAPOLB | |
| SCHEMBL4242758 | 0.80 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1POLBTSHR | |
| SCHEMBL4242762 | 0.80 | RAB9A (0.46) | RAB9ASMN1; SMN2NPC1POLBTSHR | |
| SCHEMBL4235421 | 0.78 | SMN1; SMN2 (0.35) | RAB9ASMN1; SMN2NPC1LMNATSHR | |
| SCHEMBL4235670 | 0.77 | KDM4E (0.36) | RAB9ASMN1; SMN2NPC1LMNATSHR | |
| SCHEMBL4238138 | 0.76 | TSHR (0.33) | RAB9ASMN1; SMN2NPC1LMNATSHR | |
| SCHEMBL4230793 | 0.75 | CACNA1H (0.34) | RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL12201101 | 0.74 | LMNA (0.57) | RAB9ASMN1; SMN2LMNAPOLBTSHR | |
| SCHEMBL7729255 | 0.71 | KDM4E (0.47) | RAB9ASMN1; SMN2NPC1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2009-03-12 | — | — | US | disclosed |
| US-7173053-B2 | N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| EP-1339400-B1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS | VERNALIS OXFORD LTD (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069322-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS | FPR1, FPR3, FPR2 | RAB9A 4275/4885SMN1; SMN2 4259/4885NPC1 1549/4885 |
| US-20040106666-A1 | Hydroxamic acid or n-formyl hydroxylamine derivatives as inhibitors of bakterial polypeptide deformylase for treating microbial infections | HNMT, ALKBH1, BAK1 | RAB9A 4448/4885SMN1; SMN2 3663/4885NPC1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.